Psoriatic Arthritis - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Psoriatic Arthritis - Pipeline Review, H1 2018’, provides an overview of the Psoriatic Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis

- The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects

- The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Alteogen Inc

Amgen Inc

Biocon Ltd

Bionovis SA

Coherus BioSciences Inc

Eli ...

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Alteogen Inc

Amgen Inc

Biocon Ltd

Bionovis SA

Coherus BioSciences Inc

Eli Lilly and Co

Fresenius SE & Co KGaA

FYB202 GmbH & Co KG

Galapagos NV

Genor BioPharma Co Ltd

Grunenthal GmbH

Immunwork Inc

Innovent Biologics Inc

Johnson & Johnson

Kv1.3 Therapeutics

Morphotek Inc

Mycenax Biotech Inc

Nichi-Iko Pharmaceutical Co Ltd

Nordic Group BV

Novartis AG

Nuevolution AB

Numab Innovation AG

Oncobiologics Inc

Pfizer Inc

Reliance Life Sciences Pvt Ltd

Rigel Pharmaceuticals Inc

Sandoz International GmbH

Sun Pharma Advanced Research Company Ltd

SynAct Pharma AB

UCB SA

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Psoriatic Arthritis – Overview 6

Psoriatic Arthritis – Therapeutics Development 7

Psoriatic Arthritis – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Psoriatic Arthritis – Overview 6

Psoriatic Arthritis – Therapeutics Development 7

Psoriatic Arthritis – Therapeutics Assessment 15

Psoriatic Arthritis – Companies Involved in Therapeutics Development 23

Psoriatic Arthritis – Drug Profiles 39

Psoriatic Arthritis – Dormant Projects 217

Psoriatic Arthritis – Discontinued Products 219

Psoriatic Arthritis – Product Development Milestones 220

Appendix 233

List of Tables

List of Tables

Number of Products under Development for Psoriatic Arthritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Psoriatic Arthritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Psoriatic Arthritis – Pipeline by 3SBio Inc, H1 2018

Psoriatic Arthritis – Pipeline by AbbVie Inc, H1 2018

Psoriatic Arthritis – Pipeline by AbGenomics International Inc, H1 2018

Psoriatic Arthritis – Pipeline by Aclaris Therapeutics Inc, H1 2018

Psoriatic Arthritis – Pipeline by Adello Biologics LLC, H1 2018

Psoriatic Arthritis – Pipeline by Alteogen Inc, H1 2018

Psoriatic Arthritis – Pipeline by Amgen Inc, H1 2018

Psoriatic Arthritis – Pipeline by Biocon Ltd, H1 2018

Psoriatic Arthritis – Pipeline by Bionovis SA, H1 2018

Psoriatic Arthritis – Pipeline by Coherus BioSciences Inc, H1 2018

Psoriatic Arthritis – Pipeline by Eli Lilly and Co, H1 2018

Psoriatic Arthritis – Pipeline by Fresenius SE & Co KGaA, H1 2018

Psoriatic Arthritis – Pipeline by FYB202 GmbH & Co KG, H1 2018

Psoriatic Arthritis – Pipeline by Galapagos NV, H1 2018

Psoriatic Arthritis – Pipeline by Genor BioPharma Co Ltd, H1 2018

Psoriatic Arthritis – Pipeline by Grunenthal GmbH, H1 2018

Psoriatic Arthritis – Pipeline by Immunwork Inc, H1 2018

Psoriatic Arthritis – Pipeline by Innovent Biologics Inc, H1 2018

Psoriatic Arthritis – Pipeline by Johnson & Johnson, H1 2018

Psoriatic Arthritis – Pipeline by Kv1.3 Therapeutics, H1 2018

Psoriatic Arthritis – Pipeline by Morphotek Inc, H1 2018

Psoriatic Arthritis – Pipeline by Mycenax Biotech Inc, H1 2018

Psoriatic Arthritis – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H1 2018

Psoriatic Arthritis – Pipeline by Nordic Group BV, H1 2018

Psoriatic Arthritis – Pipeline by Novartis AG, H1 2018

Psoriatic Arthritis – Pipeline by Nuevolution AB, H1 2018

Psoriatic Arthritis – Pipeline by Numab Innovation AG, H1 2018

Psoriatic Arthritis – Pipeline by Oncobiologics Inc, H1 2018

Psoriatic Arthritis – Pipeline by Pfizer Inc, H1 2018

Psoriatic Arthritis – Pipeline by Reliance Life Sciences Pvt Ltd, H1 2018

Psoriatic Arthritis – Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Psoriatic Arthritis – Pipeline by Sandoz International GmbH, H1 2018

Psoriatic Arthritis – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Psoriatic Arthritis – Pipeline by SynAct Pharma AB, H1 2018

Psoriatic Arthritis – Pipeline by UCB SA, H1 2018

Psoriatic Arthritis – Pipeline by Xbrane Biopharma AB, H1 2018

Psoriatic Arthritis – Dormant Projects, H1 2018

Psoriatic Arthritis – Dormant Projects, H1 2018 (Contd..1), H1 2018

Psoriatic Arthritis – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Psoriatic Arthritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Psoriatic Arthritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports